Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intranasal cenegermin for non-arteritic anterior ischemic optic neuropathy
MOH_2026-08-19_016998Phase 3Not yet recruiting
- Sponsor
- Dompé
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-arteritic anterior ischemic optic neuropathy (NAION) comparing Cenegermin with Vehicle control (2 arms). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
cenegermin
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on MOH_2026-08-19_016998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-19_016998.